duração da imunidade vacinal na leishmaniose visceral canina ...

Referências Bibliográficas75.MEDONÇA , S.C.; RUSSEL, D.G.; COUTINHO, S.G. Analysis of the human Tcell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG)and glycoprotein 63 (gp63). Clin. Exp. Immunol. 83, 472-478. 1991.76. GENARO, O.; DE T.; DA COSTA, C.A.; HERMETO, M.V.; AFONSO, L.C.;MAYRINK, W. Vccine for prophylaxis and immunotherapy, Brazil. Clin. Dermatol.14,503-512. 1996.77. MARZOCHI, M.C.A.; COUTINHO, S.G.; SOUZA, W.J.S.; TOLEDO, L. M.;GRIMALD, Jr.; MOMEN, H.; PACHECO, R.S.; SABROZA, P.C.; SOUZA, M. A.;RANGEL, Jr. F.B. & TRAMONTANO, N. Canine visceral leishmaniasis in Rio deJaneiro, Brazil. Clinical, Parasitological, Therapeutical and Epidemiological findings.(1977-1983). Mem. Inst. Oswaldo Cruz, 80: 349-357, 1985.78. MAYRINK, W.; SANTOS, G.C.; TOLEDO, V.P.; GUIMARÃES, T.M.;MACHADO-COELHO, G.L.; GENARO, O. & DA COSTA C.A. Vaccination ofC57/10 mice against cutaneous Leishmaniasis using killed promastigotes ofdifferente strains and species of Leishmania. Rev. soc.Bras.Med. Trop. 35: 125-132. 2002.79. VITORIANO-SOUZA, J.; REIS, A.B.; MOREIRA, N.D.; GIUNCHETTI, R.C.;CORREA-OLIVEIRA, R. ET AL. Kinetics of cell migration to the dermis andhypodermis in dogs vaccinated with antigenic compounds of Leishmaniabraziliensis plus saponin. Vaccine 26: 3922–3931. 2008.80.WEBB J.R.; KAUFMAN D.; CAMPOS-NETO A.; REED S.G. Molecular cloning ofa novel protein antigen of Leishmania major that elicits a potent immune responsein experimental murine leishmaniasis, J. Immunol. 157: 5034-5041, 1996.81. SKEIKY, Y.A.W.; GUDERIAN, J.A.; BENSON, D.R.; BACELAR, O.;CARVALHO, E.M.; KUBIN, M.; BADARO, R.; TRINCHIERI, G.;REED, S.G. Arecombinant Leishmania antigen that stimulates human peripheral bloodmononuclear cells to express a tha1-type cytokines profile and produce interleukin12. J. Exp. Med., 181: 1527-1537, 1995.82. FUJIWARA, R. T.; VALE, A. M.; FRANÇA DA SILVA, J.C ; COSTA, R.T. ;QUETZ, J. S.; MARTINS FILHO, O.A.; REIS, A.B.; OLIVEIRA, R.C.; MACHADO-COELHO, G. L.; BUENO, L.L.; BETHONY, J.M.; FRANK, G.; NASCIMENTO, E.;GENARO, O.; MAYRINK, W.; REED, S.; CAMPOS-NETO, A. Immunogenicity indogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccinecandidates for canine visceral leishmaniasis. Vet. Res., 36: 827-838, 2005.83. PALATNIK, C.B.; MORENO, M.B.; PARAGUAI DE SOUZA, E.; BOROJEVIC,R. Experimental murine Leishmania donovani infection immunoprotetion by thefucose mannose ligant (FML). Braz. J. Med. Res., 27: 547-551, 1994.84. SILVA, V.O. da.; BORJA-CABRERA, G. P.; PONTES, N.N.C.; SOUSA, E. P.;LUZ, K. G.; PALATNIK, M. & PALATNIK, C. B. S. A phase III trial of efficacy of theFML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalodo Amaranto, RN). Vaccine., 19: 1068-1081, 2001.93